

**REMARKS**

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

**Claim Amendments**

Claim 1 has been amended to incorporate the limitations of claim 2.

Claims 8, 9, 13 and 14 have been amended accordingly by limiting the pyrazolone compound to 3-methyl-1-phenyl-2-pyrazoline-5-one.

**Rejection Under 35 U.S.C. § 112, First Paragraph**

Claims 1-16 are rejected under 35 U.S.C. § 112, first paragraph, as based upon a disclosure which is not enabling has been rendered moot in view of the claim amendments.

In particular, it is noted that on page 3 of the Office Action, the Examiner indicates that the claims are enabled for the treatment of ALS (Amyotrophic Lateral Sclerosis) with Ederavone. Without acquiescence to the correctness of the Examiner's position, claims 1, 8, 9, 13 and 14 have been amended to limit the pyrazolone compound to Ederavone. Thus, Applicants respectfully suggest that this rejection, as applied to the amended claims, is untenable and should be withdrawn.

**Conclusion**

Therefore, in view of the foregoing amendments and remarks, it is submitted that the rejection set forth by the Examiner has been overcome, and that the application is in condition for allowance. Such allowance is solicited.

If, after reviewing this Amendment, the Examiner feels there are any issues remaining which must be resolved before the application can be passed to issue, the Examiner is respectfully requested to contact the undersigned by telephone in order to resolve such issues.

Respectfully submitted,

Hiide YOSHINO et al.

/William R.  
By Schmidt, II/

Digitally signed by /William R. Schmidt, II/  
DN: cn=/William R. Schmidt, II, o, ou=  
email=bschmidt@venderoth.com, c=US  
Date: 2010.08.17 11:59:09 -04'00'

William R. Schmidt  
Registration No. 58,327  
Attorney for Applicants

WRS/AES/cbc  
Washington, D.C. 20005-1503  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
August 17, 2010